Company Filing History:
Years Active: 2018
Title: Kevin Quann: Innovator in Glioblastoma Treatment
Introduction
Kevin Quann is a notable inventor based in Pittsburgh, PA, who has made significant contributions to the field of medical treatment for glioblastoma. His innovative approach focuses on utilizing caveolin-1-related methods to enhance the efficacy of temozolomide, a common chemotherapy drug used in treating this aggressive form of brain cancer.
Latest Patents
Kevin Quann holds 1 patent for his invention titled "Caveolin-1 related methods for treating glioblastoma with temozolomide." This patent outlines a method for treating subjects afflicted with glioblastoma multiforme by administering a therapeutically effective regimen of temozolomide. The invention emphasizes the importance of identifying caveolin-1-positive glioblastoma multiforme cells, as these subjects are likely to respond positively to the treatment.
Career Highlights
Quann is affiliated with Thomas Jefferson University, where he continues to advance research in cancer treatment. His work is pivotal in understanding how specific cellular markers can influence therapeutic outcomes in patients suffering from glioblastoma.
Collaborations
Kevin Quann collaborates with esteemed colleagues such as Michael P. Lisanti and Jean-Francois Jasmin, contributing to a multidisciplinary approach in cancer research and treatment.
Conclusion
Kevin Quann's innovative work in glioblastoma treatment exemplifies the critical intersection of research and practical application in medicine. His contributions are paving the way for more effective therapies for patients battling this challenging disease.